Aruna Bio

11:15 AM - 11:30 AM, Tuesday, June 4, 2019 ・ Theater 2
For over twelve years, Aruna manufactured and provided neural stem cells to the world’s leading research organizations with unrivaled uniformity and scale. Today, Aruna Bio is advancing a new class of cell-free biologics, neural exosomes, for the treatment of central nervous system (CNS) injury and degenerative disorders. As experts in the design and scaling of neural-derived exosomes, Aruna Bio is rapidly moving toward clinical development of a new class of cell-free exosome biologics and exosome-mediated drug delivery systems. To date, our exosomes have demonstrated the ability to be safely administered intravenously in multiple doses with no adverse side effects, cross the blood-brain barrier non-invasively to reach the site of injury, reduce inflammation and enhance neural function, and improve motor function and behavioral outcomes in large and small preclinical models.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Georgia
Company HQ Country:
United States
Year Founded:
2005
Main Therapeutic Focus:
Lead Product in Development:
AB126
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Chief Executive Officer
Aruna Bio